This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Repligen (RGEN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Repligen's (RGEN) third-quarter earnings call, investor focus is likely to be on the sales performance of its product franchisees - filtration, chromatography, protein and process analytics.
Should You Buy Alkermes (ALKS) Ahead of Earnings?
by Zacks Equity Research
Alkermes (ALKS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) Q3 earnings call, investor focus will likely be on updates on the company's pipeline candidates, especially its lead candidate CTX001.
Gilead (GILD) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) third-quarter 2021 results.
Top Ranked Momentum Stocks to Buy for October 18th
by Zacks Equity Research
ALKS, CMC, and E made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 18, 2021.
Top Ranked Momentum Stocks to Buy for October 13th
by Zacks Equity Research
ALKS, BP, and E made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 13, 2021.
Find 'Strong Buy' Stocks for October and Beyond with this Screener
by Benjamin Rains
Given this backdrop, investors with long-term horizons should remain on the hunt for stocks because timing the market is difficult. Utilizing our Filtered Zacks Rank 5 Stock Screener is a great place to start...
Biogen's (BIIB) MS Drug, Vumerity, Gets Positive CHMP Opinion
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends granting marketing authorization to Biogen's (BIIB) Vumerity for the treatment of adults with relapsing-remitting multiple sclerosis.
Alkermes' (ALKS) Drug Portfolio Aids Growth, High Reliance a Woe
by Zacks Equity Research
Alkermes' (ALKS) portfolio of proprietary products drives growth while its pipeline progress has been impressive. However, heavy dependence on partners for royalty revenues remains a concern.
Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone, a potential treatment for schizophrenia.
Why Is Alkermes (ALKS) Up 19.4% Since Last Earnings Report?
by Zacks Equity Research
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes (ALKS) Beats on Q2 Earnings & Sales, Ups '21 View
by Zacks Equity Research
Following a positive recovery from COVID-impacts, Alkermes (ALKS) beat both earnings and sales estimates in second-quarter 2021. The company also raised its guidance for 2021.
Alkermes (ALKS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 150.00% and 9.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: MRNA COVID-19 Vaccine Update, Drug Approvals for ALKS, MYOV & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Alkermes (ALKS), among others.
Alkermes' (ALKS) Schizophrenia, Bipolar I Disorder Drug Approved
by Zacks Equity Research
The FDA approves Alkermes' (ALKS) Lybalvi for the treatment of adults with schizophrenia or bipolar I disorder. Shares up
Alkermes (ALKS) Up 3.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes (ALKS) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 320.00% and 10.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Alkermes (ALKS) Inks Deal With Merck for Ovarian Cancer Study
by Zacks Equity Research
Alkermes (ALKS) signs a clinical trial collaboration and supply agreement with Merck to evaluate nemvaleukin alfa in combination with Keytruda for treating platinum-resistant ovarian cancer.
Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) beats both earnings and sales estimates in the fourth quarter of 2020.
Alkermes (ALKS) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Innoviva (INVA) This Earnings Season?
by Zacks Equity Research
Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter.
Will Trikafta Drive Vertex's (VRTX) Revenues in Q4 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta.
BioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo
by Zacks Equity Research
BioCryst (BCRX) gets approval in Japan for oral, once-daily Orladeyo 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years or older.
Ultragenyx's (RARE) IND for Wilson Disease Cleared by FDA
by Zacks Equity Research
Ultragenyx's (RARE) IND application for UX701 for the treatment of Wilson Disease gets FDA clearance.
Bristol Myers' (BMY) Opdivo Label Expansion Gets Priority Review
by Zacks Equity Research
Bristol Myers' (BMY) sBLA for the label expansion of Opdivo for gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma gets priority review.